Inicio › Enfermedad pulmonar intersticial › Nueva York
Ensayos clínicos de Enfermedad pulmonar intersticial en Nueva York
19 estudios sobre Enfermedad pulmonar intersticial buscan participantes en Nueva York.
Ciudades en Nueva York
Texto oficial del estudio (inglés)
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Weill Cornell Medicine-New York-60569, New York
ReclutandoFase 3
Edades de 40 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07201922A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Icahn School of Medicine at Mount Sinai, New York
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06968845Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Weill Medical College of Cornell University, New York
ReclutandoEstudio observacional
Edades de 21 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT01915511FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Weill Cornell Medicine-New York-60569, New York
- New York Presbyterian Hospital -Columbia University, New York
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07540988Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Buffalo, Buffalo
- Weill Cornell University Medical College, New York
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06911632Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA005, New York
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT07179380RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
ReclutandoFase 2/3
Edades de 18 a 75 · Todos los sexos · Actualizado el 16 oct 2026 · NCT06328777A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- NYU Langone Health, New York
- University of Rochester Medical Center, Rochester
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 14 oct 2026 · NCT07285655A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), East White Plains
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07323732A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, New York
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT05878717DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Northwell Health, New Hyde Park
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital - Weill Cornell Medicine, New York
- y 1 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06195072PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- Weill Cornell Medicine, New York
ReclutandoEstudio observacional
Edades de 18 a 80 · Todos los sexos · Actualizado el 18 ago 2026 · NCT06855329The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
- University of Rochester Medical Center, Rochester
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT07561034Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Northwell Health, New Hyde Park
- Weill Cornell Medicine, New York-Presbyterian Hospital, New York
- Stony Brook Advanced Specialty Care, Stony Brook
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT05943535Cough Capture as a Portal Into the Lung
- Albert Einstein College of Medicine, The Bronx
ReclutandoEstudio observacional
Edades de 21 en adelante · Todos los sexos · Actualizado el 13 ene 2026 · NCT05854563Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 may 2025 · NCT05892614De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.